A nitrone compound for use, in conjunction with a doxorubicin active agent, as a doxorubicin toxicity reducing adjuvant to reduce the toxicity of the doxorubicin active agent in a subject, wherein the nitrone compound has the formula: or a pharmaceutically acceptable salt, solvate or hydrate form thereof, or spatial isomer thereof; wherein: L is -.[C(R 3) 2] m -X'-[C(R 4) 2] n -; m is an integer from 0 to 6; n is an integer from 0 to 6; X' is selected from the group consisting of no atom, NR 2, O, S, SO and SO 2; Cy is selected from the group consisting of substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloheteroalkyl, bicycloalkenyl, bicycloheteroalkenyl, bicycloaryl, or bicycloheteroaryl ring; R 1 is selected from the group consisting of substituted or unsubstituted aliphatic, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaralkyl; R 2 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted aralkyl; R 3 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted aralkyl; R 4 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted aralkyl, and any two R 3 s may join together to form a cycloalkyl or a cycloheteroalkyl ring; and one of R 3 s and one of R 4 s on carbon atoms adjacent to X' may join together to form a heterocyclic ring of 5-7 atoms; and R 5 is hydrogen, thiol, or disulfide conjugate. L is -.[C(R 3) 2] m -X'-[C(R 4) 2] n -; m is an integer from 0 to 6; n is an integer from 0 to 6; X' is selected from the group consisting of no atom, NR 2, O, S, SO and SO 2; Cy is selected from the group consisting of substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloheteroalkyl, bicycloalkenyl, bicycloheteroalkenyl, bicycloaryl, or bicycloheteroaryl ring; R 1 is selected from the group consisting of substituted or unsubstituted aliphatic, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaralkyl; R 2 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted aralkyl; R 3 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted aralkyl; R 4 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted aralkyl, and any two R 3 s may join together to form a cycloalkyl or a cycloheteroalkyl ring; and one of R 3 s and one of R 4 s on carbon atoms adjacent to X' may join together to form a heterocyclic ring of 5-7 atoms; and R 5 is hydrogen, thiol, or disulfide conjugate.